Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - AILERON THERAPEUTICS INC | alrn-ex322_10.htm |
| EX-32.1 - EX-32.1 - AILERON THERAPEUTICS INC | alrn-ex321_11.htm |
| EX-31.2 - EX-31.2 - AILERON THERAPEUTICS INC | alrn-ex312_8.htm |
| EX-31.1 - EX-31.1 - AILERON THERAPEUTICS INC | alrn-ex311_12.htm |
| EX-10.27 - EX-10.27 - AILERON THERAPEUTICS INC | alrn-ex1027_815.htm |
| EX-10.26 - EX-10.26 - AILERON THERAPEUTICS INC | alrn-ex1026_814.htm |
| EX-4.3 - EX-4.3 - AILERON THERAPEUTICS INC | alrn-ex43_729.htm |
| 10-K - 10-K - AILERON THERAPEUTICS INC | alrn-10k_20191231.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (File No. 333-226650) and Form S-8 (Nos. 333-219158, 333-224785 and 333-230592) of Aileron Therapeutics, Inc. of our report dated March 30, 2020 relating to the financial statements, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
March 30, 2020